PMID: 11926722Apr 3, 2002Paper

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial

The Journal of Clinical Psychiatry
David J GoldsteinMark A Demitrack

Abstract

Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for therapeutic efficacy and safety/tolerability in the treatment of major depression. In an 8-week multicenter, double-blind, placebo-controlled study, 173 patients (aged 18-65 years) with DSM-IV major depressive disorder were randomly allocated to receive placebo (N = 70), duloxetine (N = 70), or fluoxetine, 20 mg q.d. (N = 33). Duloxetine dose was titrated in the first 3 weeks in a forced-titration regimen from 40 mg (20 mg b.i.d.) to 120 mg/day (60 mg b.i.d.). Patients were required to have a Clinical Global Impressions (CGI)-Severity of Illness scale score of at least moderate severity (> or = 4) and a 17-item Hamilton Rating Scale for Depression (HAM-D-17) total score of at least 15. Patients could not have had any current primary DSM-IV Axis I diagnosis other than major depressive disorder, or any anxiety disorder as a primary diagnosis within the past year, excluding specific phobias. The primary efficacy measurement was the HAM-D-17 total score, and secondary measures included the Montgomery-Asberg Depression Rating Scale, CGI-Severity of Illness and CGI-Improvement, and Patient Global Impression of Improvement. Safety wa...Continue Reading

Citations

Aug 4, 2004·Psychopharmacology·Stephan ChalonLuc-André Granier
Mar 1, 2006·Psychopharmacology·Akihiro TakanoTetsuya Suhara
Aug 5, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ya-Hsu YangHao-Wei Teng
May 30, 2006·European Child & Adolescent Psychiatry·Pushpal DesarkarVinod K Sinha
Sep 10, 2008·Current Pain and Headache Reports·David FishbainDaniel K Kajdasz
Dec 14, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michael J DetkeIstvan Bitter
Apr 23, 2003·Biological Psychiatry·Craig H MallinckrodtGary D Tollefson
Oct 24, 2002·Journal of Psychiatric Research·Michael J DetkeMark A Demitrack
Dec 16, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Juan Undurraga, Ross J Baldessarini
Jan 25, 2006·Journal of Palliative Medicine·Joel RaskinJ F Wernicke
May 21, 2009·The Clinical Journal of Pain·Amy S ChappellHarvey Moldofsky
Oct 6, 2007·International Clinical Psychopharmacology·Richard C SheltonMichael J Detke
Apr 15, 2008·International Clinical Psychopharmacology·Madhukar H TrivediMichael J Detke
Oct 16, 2008·International Clinical Psychopharmacology·Stephan BrechtMichael E Thase
Mar 23, 2010·International Clinical Psychopharmacology·Giorgio Racagni, Maurizio Popoli
May 28, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·V SkljarevskiM Backonja
Nov 17, 2010·International Journal of Clinical Practice·D SagmanJ Raskin
Mar 27, 2009·Psychotherapy and Psychosomatics·Bret R RutherfordSteven P Roose
Jan 8, 2004·Psychosomatics·David J GoldsteinMark A Demitrack
Aug 30, 2007·BMC Psychiatry·James I HudsonMichael J Detke
Jun 10, 2006·Arthritis Research & Therapy·Lesley M Arnold
Jun 9, 2009·Clinical Interventions in Aging·Maya Basu, Jonathan R A Duckett
Oct 3, 2008·Neuropsychiatric Disease and Treatment·Nurcan UçeylerClaudia Sommer
Apr 1, 2007·Neuropsychiatric Disease and Treatment·David J Goldstein
Jun 13, 2008·CNS Drugs·Atsuo NakagawaUNKNOWN Multiple Meta-Analyses of New-Generation Antidepressants (MANGA) Study Group
Oct 30, 2004·Primary Care Companion to the Journal of Clinical Psychiatry·J Sloan Manning
Sep 12, 2006·Primary Care Companion to the Journal of Clinical Psychiatry·J Craig NelsonMichael J Detke
Jan 20, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Thomas N WiseCurtis G Wiltse
Jun 13, 2012·European Journal of Clinical Pharmacology·Linda HärmarkKees van Grootheest
Dec 21, 2004·Der Internist·M OelkeU Jonas
Jun 24, 2004·Journal of General Internal Medicine·Robert D KeeleyKathryn M Rost
Jan 1, 2009·International Journal of Psychiatry in Clinical Practice·Romera IreneGilaberte Inmaculada
Jan 1, 2008·International Journal of Psychiatry in Clinical Practice·Khalil AjelDavid Baldwin
Jul 1, 2003·Expert Review of Neurotherapeutics·Michael Berk

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Michael J DetkeIstvan Bitter
The Journal of Clinical Psychiatry
Joel RaskinMargaret B Ferguson
© 2022 Meta ULC. All rights reserved